Introduction
Mircette (desogestrel/ethinyl estradiol 0.15 mg/0.02 mg in a 21/7 regimen with ethinyl estradiol 0.01 mg during the last 5 days of the cycle) is a combined oral contraceptive (COC) that has been available for several decades. Unlike traditional 21/7 pill packs, Mircette incorporates a shortened hormone-free interval (5 days of low-dose estrogen versus 7 days of placebo) to reduce the risk of ovulation and provide better cycle control. Despite its established pharmacology, real-world observational data on long-term adherence, side-effect profiles, and user satisfaction remain limited. This single-center, prospective observational study followed 350 women over 24 months to evaluate the real-world performance of Mircette.
Methods
Women aged 18–40 years who initiated Mircette for contraception between January 2020 and December 2021 were enrolled. Exclusion criteria included contraindications to COCs (e.g., history of thromboembolism, uncontrolled hypertension, migraine with aura). Participants completed baseline questionnaires on menstrual history, contraceptive use, and lifestyle. Follow-ups occurred at 3, 6, 12, and 24 months via clinic visits or telemedicine. Data collected included breakthrough bleeding (BTB), amenorrhea, cycle length, pill compliance, side effects (nausea, headache, breast tenderness, mood changes), weight, blood pressure, and reasons for discontinuation. A total of 312 women (89.1%) completed 12 months, and 274 (78.3%) completed 24 months.
Results
Cycle control and bleeding patterns: At 12 months, 72% of participants reported "excellent" cycle control (no BTB or spotting). BTB occurred in 18% of cycles during months 1–3 but decreased to 6% by months 10–12. Amenorrhea (absence of withdrawal bleeding) was reported by 8% at 6 months and 11% at 12 months, consistent with known effects of estrogen-containing pills. The incidence of dysmenorrhea decreased from 44% at baseline to 12% at 12 months (p<0.001).
Adherence and continuation: Self-reported perfect pill use (no missed pills) was 88% at 3 months, declining to 75% at 12 months and 63% at 24 months. Common reasons for missed doses included travel (34%), schedule change (28%), and forgetfulness (22%). Despite this, only 3 unintended pregnancies occurred over 24 months (Pearl Index ≈ 1.0), demonstrating good real-world effectiveness. Continuation rates: 89% at 6 months, 78% at 12 months, and 62% at 24 months. Primary reasons for discontinuation were desire for pregnancy (28%), side effects (24%), and nonhormonal method preference (18%).
Side effects: The most frequently reported side effects at any point were nausea (24% at month 1, dropping to 9% by month 6), headache (31% at month 1, 19% at month 12), breast tenderness (27% at month 1, 12% at month 12), and mood changes (18% at month 1, 15% at month 12). Weight gain >2 kg was noted in 11% of participants at 12 months, while 9% lost >2 kg. Mean systolic blood pressure increased slightly (mean +2.1 mmHg, p=0.03) but remained within normal range. No venous thromboembolic events were reported.
Subgroup observations: Women with a history of acne (n=68) reported a 65% reduction in acne lesions at 12 months. Users aged 30–40 had lower rates of breakthrough bleeding compared to those aged 18–24 (5% vs. 12% at month 12, p=0.02).
Discussion
This observational study confirms that Mircette provides effective contraception with a cycle control profile that is comparable to or better than traditional 21/7 COCs. The low incidence of BTB after the first three months is notable and likely owes to the shortened hormone-free interval. The study also highlights that while initial side effects are common, they diminish over time—a pattern well-documented for ethinyl estradiol–containing contraceptives. Mood changes, however, remained persistent in a subset of users and warrant counseling.
The continuation rate at 24 months (62%) is slightly higher than the average reported for COCs (around 50% at 1 year in some populations), possibly reflecting the improved tolerability of Mircette’s regimen or the close follow-up in this study. The low pregnancy rate despite imperfect adherence underscores the forgiveness of missed pills in the Mircette schedule due to the estrogen-only replacement during the hormone-free interval.
Limitations include the single-center design, lack of a comparator group, and reliance on self-reported adherence. Selection bias toward women willing to participate in a long-term study may limit generalizability. Dropout rates were higher after 12 months, likely due to loss to follow-up rather than adverse effects alone.
Conclusion
In this real-world observational cohort, Mircette demonstrated high contraceptive efficacy, favorable cycle control, and BautyFarmacia acceptable tolerability over 24 months. The majority of users experienced improvement in menstrual pain and minimal bleeding irregularities after the initial adjustment period. Clinicians should consider Mircette for women seeking a COC with a shortened hormone-free interval, especially those prone to breakthrough bleeding with standard pills. Continued follow-up and further research into mood-related side effects and long-term metabolic effects are warranted.
